Menu
Search Close

Company

Overview

Cancer remains one of the world’s most significant diseases. A key challenge in the fight against cancer is that many tumours continue to grow by successfully evading the body’s own natural defence mechanism - the immune system. Scancell’s mission is to overcome this breach in our defences by developing products that stimulate the immune system to treat or prevent cancer.

The company, which was founded in 1997 as a spin-out from the University of Nottingham, has secured £23 million funding to date. In December 2006 Scancell sold its pipeline of direct killing monoclonal antibodies to Arana Therapeutics, an Australian biopharmaceutical company. The deal allowed Scancell to focus its efforts entirely on its innovative ImmunoBody® and Moditope® cancer vaccine programmes.

Scancell’s first cancer vaccine, SCIB1, is being developed for the treatment of melanoma and is in Phase I/II clinical trials. The initial results have been highly encouraging and suggest that SCIB1 could have an important future role as first line treatment for patients with resected Stage II or III disease, a key area of unmet medical need for which there are no effective and safe treatment options available.

Webcasts, Interviews and Media Coverage

Scancell in vanguard of immuno-oncology advances, with two technologies that show early promise

The AIM-listed group is at the vanguard of advances in the emerging field of immuno-oncology and is working on two technologies that are showing early promise

Tue, 12 Feb 2019 15:07:00

Scancell lauds another six months of progress

The funds raised in the last year "will allow us to focus on initiating the planned Phase 2 clinical trial for our lead ImmunoBody, SCIB1, and to advance our Moditope products, Modi-1 and Modi-2, towards the clinic".

Thu, 31 Jan 2019 08:41:00

Award shortlist 'a significant scientific endorsement' of Scancell's technology

Cliff Holloway, chief executive of Scancell Holdings Plc (LON:SCLP), tells Proactive London's Andrew Scott the company's received “significant scientific endorsement” of its technology after it and a group of collaborators were shortlisted for a major award.

It teamed up with BioNTech, Genentech and ISA Pharmaceuticals to form Project Blueprint for Cancer Research UK’s Grand Challenge.

The team outlined plans to eradicate established tumours with its unique vaccine, which had Scancell’s Modi-3 treatment at its heart.

Wed, 23 Jan 2019 12:25:00